JP2014517690A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517690A5
JP2014517690A5 JP2014510413A JP2014510413A JP2014517690A5 JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5 JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5
Authority
JP
Japan
Prior art keywords
noc
nucleic acid
multimer
igg2ah
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/036975 external-priority patent/WO2012154759A2/en
Publication of JP2014517690A publication Critical patent/JP2014517690A/ja
Publication of JP2014517690A5 publication Critical patent/JP2014517690A5/ja
Pending legal-status Critical Current

Links

JP2014510413A 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体 Pending JP2014517690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016204089A Division JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体

Publications (2)

Publication Number Publication Date
JP2014517690A JP2014517690A (ja) 2014-07-24
JP2014517690A5 true JP2014517690A5 (https=) 2015-06-25

Family

ID=47139949

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014510413A Pending JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Country Status (8)

Country Link
US (3) US20140065113A1 (https=)
EP (1) EP2707021B1 (https=)
JP (5) JP2014517690A (https=)
CN (2) CN103930439A (https=)
AU (1) AU2012253652B2 (https=)
CA (1) CA2835453A1 (https=)
IL (1) IL229316B (https=)
WO (1) WO2012154759A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
WO2012154759A2 (en) * 2011-05-09 2012-11-15 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
CA2901893C (en) * 2013-02-20 2022-08-30 Minerva Biotechnologies Corporation Nme inhibitors and methods of using nme inhibitors
AU2015332389A1 (en) * 2014-10-16 2017-04-20 Myriad Women's Health, Inc. Variant caller
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033810T2 (de) * 1989-10-18 2002-03-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1397484A4 (en) * 2001-03-27 2005-05-25 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH FGF DIMERIZATION
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
CN102272290B (zh) * 2008-10-09 2018-08-14 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2011103049A2 (en) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP2686418A4 (en) * 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
WO2012154759A2 (en) * 2011-05-09 2012-11-15 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Similar Documents

Publication Publication Date Title
JP2014517690A5 (https=)
US20240279303A1 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
JP7227290B2 (ja) キメラ抗原受容体、組成物及び方法
JP6965311B2 (ja) 二重特異的融合タンパク質
JP2017061471A5 (https=)
CN102781960B (zh) Hsa相关组合物及使用方法
JP2019516663A5 (https=)
JP2013541335A5 (https=)
WO2010105573A1 (zh) 抗血管新生融合蛋白
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
JP2022002528A (ja) 組織修復のための二重特異性治療用タンパク質
JP2011525363A5 (https=)
JP2017529059A5 (https=)
WO2014178078A2 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
JP7794421B2 (ja) 腫瘍を標的にする合成アデノウイルスおよびその使用
JP2014510519A5 (https=)
US20140234316A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
JP2022541761A5 (https=)
JP2025137512A (ja) 新規に設計された共局在化依存性タンパク質スイッチを使用する超特異的細胞標的化
CN103342744B (zh) 一种血管新生蛋白及其应用
CN107298714A (zh) 一种双靶标融合蛋白及其制备方法和用途
SE0901565A1 (sv) Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013545440A (ja) マカカ・ファシキュラリス（Ｍａｃａｃａｆａｓｃｉｃｕｌａｒｉｓ）ＣＣＬ１７
CN106908605A (zh) eLtaS蛋白作为预防和治疗胰岛素抵抗相关疾病的药物靶点的应用
CN119798408A (zh) 一种识别hpv多抗原表位的tcr及其编码序列